ONCT — Oncternal Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.56m
- -$13.02m
- $0.79m
U.S. STOCKS ON THE MOVE-Twitter Inc, Raytheon Technologies, Autodesk Inc, Tesla Inc
U.S. STOCKS ON THE MOVE-Roku Inc, ClearSign Technologies, Costco, Zscaler
Oncternal gains on new cancer antibody drug data
Brief: Oncternal Therapeutics Presents Updated Interim Data For Zilovertamab In Combination With Ibrutinib At Asco 2022
Brief: Oncternal Therapeutics Provides Business Update And Announces First Quarter 2022 Financial Results
Oncternal Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Oncternal Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
More positive news needed to lift pressured biotech sector- Jefferies
Oncternal falls after deprioritizing development of bone cancer therapy
Brief: Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab
Oncternal Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Oncternal Therapeutics Provides Business Update And Announces Fourth Quarter And Full Year 2021 Financial Results
Oncternal Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Oncternal Therapeutics Announces Agreement With U.S. FDA On Phase 3 Registrational Study Design For Zilovertamab In The Treatment Of Mantle Cell Lymphoma
Brief: Oncternal Therapeutics Says Entered Into Open Market Sale Agreement
U.S. STOCKS ON THE MOVE-Harley-Davidson, Dollar Tree, Novavax, U.S. travel stocks
Oncternal Therapeutics rises on cancer antibody study data
Brief: Oncternal Therapeutics Presents Updated Interim Data For Zilovertamab In Combination With Ibrutinib At ASH 2021
Brief: Oncternal Therapeutics Presented Updated Interim Phase 1/2 Clinical Trial Data For ONCT-216 In Patients With Relapsed/Refractory Ewing Sarcoma At Ctos 2021 Virtual Annual Meeting